SMAD3 and melanoma: Importantly, a subset of BRAF(V600E) melanoma patients (~20%) expressing the SMAD3‐signature was identified (Fig 7E), suggesting that these tumors contained dedifferentiated melanoma cells with potential intrinsic resistance to BRAFi.